Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?

Novo Nordisk (NVO) shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its next-generation subcutaneous obesity candidate, CagriSema. Per the data readout from the phase III REDEFINE 1 study, a weight loss of 22.7% was observed in patients treated with CagriSema, which missed NVO’s guidance of 25% weight loss at week 68, provided on the third-quarter earnings conference call.Novo Nordisk’s failure favors its arch-rival in the obesity market space, Eli Lil ...